Pathophysiology of thyroid eye disease/thyroid orbitopathy and teprotumumab: In orbitopathy, it is believed that there is a cross reaction of thyroid auto-antibodies with the thyrotropin receptor (TSHR) and the insulin growth factor receptor (IGFR) on orbital fibroblasts.
Date
2023-03
References
1. Khong JJ et al. Medical treatment in thyroid eye disease in 2020. Br J Ophthalmol. 2021; 105: 299-305. doi: 10/1136/bjophthalmol-2020-316051. 2. Douglas, R. S. et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. New England Journal of Medicine 2020; 382:341-352. doi: 10.1056/NEJMoa1910434. 3. Douglas, R. S. et al. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-Treatment. Ophthalmology April 2022; 129(4): 438-449. doi: 10.1016/j.ophtha.2021.10.017. 4. Haymart, Megan R. Year in Thyroidology-Recent Developments and Future Challenges: Clinical Science Review. Thyroid 2022 32(1):9-13. doi: 10.1089/thy.2021.0562. 5. Bhatti and Dutton. Thyroid Eye Disease: Therapy in the Active Phase. J Neuro-ophthalmol 2014; 34:186-197. doi: 10.1097/wno.0000000000000128.
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2023 North American Neuro-Ophthalmology Society Annual Meeting
